VISEN MEDICAL INC
- Headquarters
- Bedford, MA
- Latest Form D
- $885K, Oct 2009
- Total capital
- $4.3M
- Federal grants
- $3.5M
- 13 awards · 2002–2005
- Private capital raised
- $885K
- 1 Form D · last Oct 2009
- 205 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 19
- 21 pending · first 2014
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$885K
- Federal grantHealth and Human S · Phase II · Fluorescence Endoscopy for Enhanced Adenoma Detection$100K
- Federal grantHealth and Human S · Phase II · Targeted Magnetic Nanoparticles for Clinical Imaging$100K
- Federal grantHealth and Human S · Phase II · Targeted Magnetic Nanoparticles for Clinical Imaging$331K
- Federal grantHealth and Human S · Phase II · Targeted Magnetic Nanoparticles for Clinical Imaging$372K
- Federal grantHealth and Human S · Phase II · Imaging system for in vivo fluorescence quantification$474K
- Federal grantHealth and Human S · Phase II · Imaging system for in vivo fluorescence quantification$464K
Show 7 earlier federal awards
- Federal grantHealth and Human S · Phase II · Imaging system for in vivo fluorescence quantification$467K
- Federal grantHealth and Human S · Phase II · Imaging system for in vivo fluorescence quantification$98K
- Federal grantHealth and Human S · Phase I · Development of MMP-13 Molecular Imaging Probes$100K
- Federal grantHealth and Human S · Phase I · Metabolite Probes for Molecular Optical Imaging$100K
- Federal grantHealth and Human S · Phase II · Molecular Beacons for Clinical Cancer Imaging$298K
- Federal grantHealth and Human S · Phase II · Molecular Beacons for Clinical Cancer Imaging$450K
- Federal grantHealth and Human S · Phase I · Molecular Beacons for Clinical Cancer Imaging$99K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
89months
from VISEN MEDICAL INC’s first federal award to its first private round.
- First federal award · May 2002
- Health and Human S · $99K
- First Form D · Oct 2009
- $885K · 1st Form D
- Awards before first raise
- 13 awards
An association in public records, not a cause or a prediction.
Founders and team
Researcher links verified by same-company patents and grants- Kirtland G. H. PossResearcherDirector, Executive OfficerLinked by $1.5M in grants as PI
- Ed KaniaDirectorNamed in SEC Form D filings
- Erik G. H. WalldenDirectorNamed in SEC Form D filings
- John G. H. ZiolkowskiExecutive OfficerNamed in SEC Form D filings
- Per G. H. LofbergDirectorNamed in SEC Form D filings
- Ralph G. H. Weissleder, Ph.D.DirectorNamed in SEC Form D filings
What it has protected
USPTO · 19 granted of 40- Pending4,4-DISUBSTITUTED Cyclohexyl Bridged Heptamethine Cyanine Dyes And Uses ThereofUSPTOApplication 18675875
- GrantedCarbonic Anhydrase Targeting Agents And Methods Of Using SameUSPTOUS 12,110,283
- GrantedSystems, Methods, and Apparatus for Imaging of Diffuse Media Featuring Cross-Modality Weighting of Fluorescent and Bioluminescent SourcesUSPTOUS 11,903,675
Show all 40 patent records
- 4,4-DISUBSTITUTED Cyclohexyl Bridged Heptamethine Cyanine Dyes And Uses ThereofNov 28, 2024 · Application 18675875Pending
- Carbonic Anhydrase Targeting Agents And Methods Of Using SameOct 8, 2024 · US 12,110,283Granted
- Systems, Methods, and Apparatus for Imaging of Diffuse Media Featuring Cross-Modality Weighting of Fluorescent and Bioluminescent SourcesFeb 20, 2024 · US 11,903,675Granted
- 4,4-DISUBSTITUTED Cyclohexyl Bridged Heptamethine Cyanine Dyes And Uses ThereofJun 9, 2022 · Application 17454300Pending
- 4,4-DISUBSTITUTED Cyclohexyl Bridged Heptamethine Cyanine Dyes And Uses ThereofDec 7, 2021 · US 11,193,932Granted
- Carbonic Anhydrase Targeting Agents And Methods Of Using SameJul 13, 2021 · US 11,059,802Granted
- Systems, Methods, and Apparatus for Imaging of Diffuse Media Featuring Cross-Modality Weighting of Fluorescent and Bioluminescent SourcesAug 18, 2020 · US 10,743,768Granted
- 4,4-DISUBSTITUTED Cyclohexyl Bridged Heptamethine Cyanine Dyes And Uses ThereofNov 12, 2019 · US 10,473,658Granted
- Biocompatible N, N-Disubstituted Sulfonamide-Containing Fluorescent Dye LabelsOct 15, 2019 · US 10,442,930Granted
- Methods And Compositions For Identifying Subjects At Risk Of Developing Stent ThrombosisOct 9, 2018 · US 10,092,188Granted
- Fluorescent Imaging AgentsJun 19, 2018 · US 9,999,687Granted
- Systems And Methods For Virtual Index-matching Of Diffusive MediaFeb 27, 2018 · US 9,901,254Granted
- 4,4-DISUBSTITUTED Cyclohexyl Bridged Heptamethine Cyanine Dyes And Uses ThereofFeb 20, 2018 · US 9,897,604Granted
- Substituted Silaxanthenium Red To Near-infrared Fluorochromes For In Vitro And In Vivo Imaging And DetectionMay 16, 2017 · US 9,649,389Granted
- Fluorescent Imaging AgentsAug 30, 2016 · US 9,427,481Granted
- Bacterial Imaging Agents And Methods Of Using SameJun 28, 2016 · US 9,375,493Granted
- Prostate Specific Antigen Agents And Methods Of Using Same For Prostate Cancer ImagingJun 21, 2016 · US 9,371,362Granted
- Imaging Systems Featuring Waveguiding CompensationApr 12, 2016 · US 9,311,722Granted
- Imaging Volumes With Arbitrary Geometries In Non-contact TomographyFeb 3, 2015 · US 8,948,852Granted
- Nicotinic Acid and Picolinic Acid Derived Near-Infrared FluorophoresJul 8, 2014 · US 8,771,646Granted
- Imaging Systems Featuring Waveguiding CompensationFeb 18, 2014 · US 8,653,480Granted
- Nicotinic Acid And Picolinic Acid Derived Near-infrared FluorophoresApplication PCTUS2006034406Pending
- Biocompatible Fluorescent Silicon NanoparticlesApplication PCTUS2004018023Pending
- Imaging Volumes With Arbitrary Geometries In Contact And Non- Contact TomographyApplication PCTUS2003017558Pending
- Chromophore Probes For Optical ImagingApplication PCTUS2003001346Pending
- 4,4-DISUBSTITUTED Cyclohexyl Bridged Heptamethine Cyanine Dyes And Uses ThereofApplication PCTUS2014029224Pending
- Substituted Silaxanthenium Red To Near-infrared Fluorochromes For In Vitro And In Vivo Imaging And DetectionApplication PCTUS2014029350Pending
- Systems, Methods, And Apparatus For Imaging Of Diffuse Media Featuring Cross-modality Weighting Of Fluorescent And Bioluminescent SourcesApplication PCTUS2013065107Pending
- Substituted Silaxanthenium Near-infrared Dyes For In Vitro And In Vivo ImagingApplication 61794188Pending
- Prostate Specific Antigen Agents And Methods Of Using Same For Prostate Cancer ImagingApplication PCTUS2013032200Pending
- Bacterial Imaging Agents And Methods Of Using SameApplication PCTUS2013032126Pending
- 4,4-DISUBSTITUTED Cyclohexyl Bridged Heptamethine Cyanine Dyes And Uses ThereofApplication 61798562Pending
- Systems, Methods, and Apparatus for Imaging of Diffuse Media Featuring Cross-Modality Weighting of Fluorescent and Bioluminescent SourcesApplication 61714198Pending
- Carbonic Anhydrase Targeting Agents And Methods Of Using SameApplication PCTUS2012037166Pending
- Systems And Methods For Virtual Index-matching Of Diffusive MediaApplication PCTUS2010049831Pending
- Systems And Methods For Tomographic Imaging In Diffuse Media Using A Hybrid Inversion TechniqueApplication PCTUS2010046973Pending
- Animal Holder For In Vivo Tomographic Imaging With Multiple ModalitiesApplication PCTUS2009038213Pending
- Fluorescent Imaging AgentsApplication PCTUS2009031364Pending
- Imaging Systems Featuring Waveguiding CompensationApplication PCTUS2008065648Pending
- Viable Near-infrared Fluorochrome Labeled Cells And Methods Of Making And Using SameApplication PCTUS2008056235Pending
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .